- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05552976
En undersøgelse til evaluering af CC-92480 i kombination med carfilzomib og dexamethason (480Kd) versus carfilzomib og dexamethason (Kd) hos deltagere med recidiverende eller refraktær myelomatose (SUCCESSOR-2)
Et fase 3, to-trins, randomiseret, multicenter, åbent studie, der sammenligner CC-92480 (BMS-986348), Carfilzomib og Dexamethason (480Kd) versus Carfilzomib og Dexamethason (Kd) hos deltagere med recidiverende RR- eller Refractory )
The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
-
Buenos Aires, Argentina, 1431
- Local Institution - 0150
-
Córdoba, Argentina, 5000
- Local Institution - 0151
-
-
Buenos Aires
-
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, C1426ANZ
- Local Institution - 0008
-
-
Buenos Aires F.D.
-
ABB, Buenos Aires F.D., Argentina, C1199ABB
- Local Institution - 0079
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Argentina, 2000
- Local Institution - 0182
-
-
Tucumán Province
-
San Miguel de Tucumán, Tucumán Province, Argentina, 4000
- Local Institution - 0319
-
-
-
-
New South Wales
-
Camperdown, New South Wales, Australien, 2050
- Local Institution - 0077
-
Gosford, New South Wales, Australien, 2250
- Local Institution - 0160
-
Port Macquarie, New South Wales, Australien, 2444
- Local Institution - 0263
-
St Leonards, New South Wales, Australien, 2065
- Local Institution - 0078
-
Sydney, New South Wales, Australien, 2010
- Local Institution - 0026
-
-
South Australia
-
Adelaide, South Australia, Australien, 5000
- Local Institution - 0024
-
-
Victoria
-
Bendigo, Victoria, Australien, 3550
- Local Institution - 0131
-
East Melbourne, Victoria, Australien, 3002
- Local Institution - 0224
-
Heidelberg, Victoria, Australien, 3084
- Local Institution - 0127
-
Melbourne, Victoria, Australien, 3065
- Local Institution - 0025
-
-
-
-
-
Rio de Janeiro, Brasilien, 20775-001
- Local Institution - 0075
-
São Paulo, Brasilien, 04537-080
- Local Institution - 0073
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brasilien, 41253-190
- Local Institution - 0121
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brasilien, 90470-340
- Local Institution - 0076
-
-
São Paulo
-
São Paulo, São Paulo, Brasilien, 01509-010
- Local Institution - 0085
-
-
-
-
-
Plovdiv, Bulgarien, 4002
- Local Institution - 0305
-
Sofia, Bulgarien, 1407
- Local Institution - 0309
-
Sofia, Bulgarien, 1431
- Local Institution - 0304
-
-
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 2Y9
- Local Institution - 0183
-
-
Ontario
-
London, Ontario, Canada, N6A 5W9
- Local Institution - 0275
-
Toronto, Ontario, Canada, M5G 2M9
- Local Institution - 0184
-
-
-
-
-
Cali, Colombia, 760035
- Local Institution - 0155
-
-
Antioquia
-
Medellín, Antioquia, Colombia, 05034
- Local Institution - 0153
-
-
Cesar Department
-
Valledupar, Cesar Department, Colombia, 200001
- Local Institution - 0156
-
-
Cundinamarca
-
Bogota, Cundinamarca, Colombia, 111151
- Local Institution - 0154
-
-
Santander Department
-
Piedecuesta, Santander Department, Colombia, 681017
- Local Institution - 0324
-
-
-
-
-
Vejle, Danmark, 7100
- Local Institution - 0125
-
-
Central Jutland
-
Aarhus, Central Jutland, Danmark, 8200
- Local Institution - 0032
-
-
Region Sjælland
-
Roskilde, Region Sjælland, Danmark, 4000
- Local Institution - 0065
-
-
Region Syddanmark
-
Odense, Region Syddanmark, Danmark, 5000
- Local Institution - 0129
-
-
-
-
-
Birmingham, Det Forenede Kongerige, B9 5SS
- Local Institution - 0273
-
Leeds, Det Forenede Kongerige, LS9 7TF
- Local Institution - 0080
-
Taunton, Det Forenede Kongerige, TA1 5DA
- Local Institution - 0040
-
-
Devon
-
Plymouth, Devon, Det Forenede Kongerige, Pl6 8DH
- Local Institution - 0139
-
-
England
-
Cringleford, England, Det Forenede Kongerige, NR4 7UY
- Local Institution - 0067
-
-
Glasgow City
-
Glasgow, Glasgow City, Det Forenede Kongerige, G12 0YN
- Local Institution - 0196
-
-
-
-
Alabama
-
Mobile, Alabama, Forenede Stater, 36604
- Local Institution - 0046
-
-
California
-
Cerritos, California, Forenede Stater, 90703
- Local Institution - 0005
-
Irvine, California, Forenede Stater, 92618
- Local Institution - 0190
-
Los Angeles, California, Forenede Stater, 90017
- Local Institution - 0187
-
Santa Rosa, California, Forenede Stater, 95403
- Local Institution - 0344
-
Stockton, California, Forenede Stater, 95204
- Local Institution - 0339
-
-
Florida
-
Fort Myers, Florida, Forenede Stater, 33901
- Local Institution - 0341
-
St. Petersburg, Florida, Forenede Stater, 33705
- Local Institution - 0342
-
West Palm Beach, Florida, Forenede Stater, 33401
- Local Institution - 0340
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30303
- Local Institution - 0348
-
Atlanta, Georgia, Forenede Stater, 30322
- Local Institution - 0291
-
-
Idaho
-
Boise, Idaho, Forenede Stater, 83706
- Saint Alphonsus Regional Medical Center
-
-
Maryland
-
Annapolis, Maryland, Forenede Stater, 21401
- Local Institution - 0289
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02215
- Local Institution - 0204
-
-
Minnesota
-
Minneapolis, Minnesota, Forenede Stater, 55404
- Local Institution - 0346
-
-
New Jersey
-
Little Silver, New Jersey, Forenede Stater, 07739
- Local Institution - 0222
-
-
New York
-
The Bronx, New York, Forenede Stater, 10467
- Local Institution - 0199
-
-
Ohio
-
Cleveland, Ohio, Forenede Stater, 44106
- Local Institution - 0322
-
Columbus, Ohio, Forenede Stater, 43214
- Local Institution - 0172
-
-
Rhode Island
-
Providence, Rhode Island, Forenede Stater, 02903
- Local Institution - 0321
-
-
South Carolina
-
Greer, South Carolina, Forenede Stater, 29650
- Local Institution - 0338
-
-
Tennessee
-
Chattanooga, Tennessee, Forenede Stater, 37404
- Local Institution - 0349
-
Nashville, Tennessee, Forenede Stater, 37203
- Local Institution - 0323
-
-
Texas
-
Fort Worth, Texas, Forenede Stater, 76104
- Local Institution - 0337
-
Houston, Texas, Forenede Stater, 77025
- Local Institution - 0328
-
Houston, Texas, Forenede Stater, 77030
- Local Institution - 0044
-
Temple, Texas, Forenede Stater, 76508
- Local Institution - 0195
-
-
Virginia
-
Norfolk, Virginia, Forenede Stater, 23502
- Local Institution - 0345
-
Roanoke, Virginia, Forenede Stater, 24014
- Local Institution - 0343
-
-
Washington
-
Tacoma, Washington, Forenede Stater, 98405
- Local Institution - 0006
-
Vancouver, Washington, Forenede Stater, 98684
- Local Institution - 0347
-
-
West Virginia
-
Morgantown, West Virginia, Forenede Stater, 26506
- Local Institution - 0243
-
-
Wisconsin
-
Marshfield, Wisconsin, Forenede Stater, 54449
- Local Institution - 0336
-
-
-
-
Achaḯa
-
Pátrai, Achaḯa, Grækenland, 26504
- Local Institution - 0136
-
-
Attikí
-
Athens, Attikí, Grækenland, 11528
- Local Institution - 0135
-
-
Thessaloníki
-
Thessaloniki, Thessaloníki, Grækenland, 570 10
- Local Institution - 0134
-
-
-
-
-
Enschede, Holland, 7512 KZ
- Local Institution - 0194
-
-
North Brabant
-
Breda, North Brabant, Holland, 4818 CK
- Local Institution - 0113
-
-
-
-
-
Hksar, Hong Kong
- Local Institution - 0178
-
-
-
-
-
Chandigarh, Indien, 160012
- Local Institution - 0230
-
-
Haryana
-
Gurgaon, Haryana, Indien, 122001
- Local Institution - 0167
-
-
Karnataka
-
Bengaluru, Karnataka, Indien, 560027
- Local Institution - 0161
-
-
Maharashtra
-
Mumbai, Maharashtra, Indien, 400012
- Local Institution - 0168
-
Thane, Maharashtra, Indien, 400602
- Local Institution - 0171
-
-
National Capital Territory of Delhi
-
New Delhi, National Capital Territory of Delhi, Indien, 110085
- Local Institution - 0170
-
-
Punjab
-
Mohali, Punjab, Indien, 160055
- Local Institution - 0261
-
-
Tamil Nadu
-
Chennai, Tamil Nadu, Indien, 600036
- Local Institution - 0174
-
-
Telangana
-
Hyderabad, Telangana, Indien, 500033
- Local Institution - 0165
-
Hyderabad, Telangana, Indien, 500068
- Local Institution - 0310
-
Hyderabad, Telangana, Indien, 500084
- Local Institution - 0164
-
-
-
-
-
Jerusalem, Israel, 9112001
- Local Institution - 0277
-
-
Central District
-
Holon, Central District, Israel, 5810001
- Local Institution - 0264
-
Tsrifin, Central District, Israel, 70300
- Local Institution - 0267
-
-
-
-
-
Bologna, Italien, 40138
- Local Institution - 0189
-
Catanzaro, Italien, 88100
- Local Institution - 0148
-
Lecce, Italien, 73100
- Local Institution - 0147
-
Pisa, Italien, 56100
- Local Institution - 0144
-
Udine, Italien, 33100
- Local Institution - 0146
-
-
Emilia-Romagna
-
Meldola, Emilia-Romagna, Italien, 47014
- Local Institution - 0145
-
-
Lombardy
-
Milan, Lombardy, Italien, 20122
- Local Institution - 0143
-
-
Milano
-
Rozzano, Milano, Italien, 20089
- Local Institution - 0142
-
-
-
-
-
Chiba, Japan, 260-8677
- Local Institution - 0215
-
Fukuoka, Japan, 810-8563
- Local Institution - 0226
-
Fukuoka, Japan, 815-8555
- Local Institution - 0235
-
Kumamoto, Japan, 860-8556
- Local Institution - 0220
-
Kyoto, Japan, 602-8566
- Local Institution - 0216
-
Nagasaki, Japan, 852-8104
- Local Institution - 0213
-
Okayama, Japan, 701-1192
- Local Institution - 0212
-
Osaka, Japan, 545-8586
- Local Institution - 0301
-
Tokyo, Japan, 105-8461
- Local Institution - 0241
-
Tokyo, Japan, 150-8935
- Local Institution - 0218
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japan, 467-8602
- Local Institution - 0269
-
-
Chiba
-
Kashiwa, Chiba, Japan, 277-8577
- Local Institution - 0214
-
-
Fukuoka
-
Kitakyushu-shi, Fukuoka, Japan, 806-8501
- Local Institution - 0210
-
-
Hokkaido
-
Sapporo, Hokkaido, Japan, 003-0804
- Local Institution - 0211
-
-
Ibaraki
-
Higashiibaraki, Ibaraki, Japan, 3113117
- Local Institution - 0217
-
-
Ishikawa-ken
-
Kanazawa, Ishikawa-ken, Japan, 920-8641
- Local Institution - 0300
-
-
Iwate
-
Shiwa-gun Yahaba-cho, Iwate, Japan, 028-3695
- Local Institution - 0209
-
-
Kanagawa
-
Kamakura, Kanagawa, Japan, 247-8533
- Local Institution - 0234
-
-
Saitama
-
Koshigaya, Saitama, Japan, 343-0845
- Local Institution - 0225
-
-
Tokyo
-
Koto-ku, Tokyo, Japan, 135-8550
- Local Institution - 0219
-
tabashi City, Tokyo, Japan, 173-8610
- Local Institution - 0236
-
-
Yamanashi
-
Chūō, Yamanashi, Japan, 409-3898
- Local Institution - 0303
-
-
-
-
-
Taiyuan, Kina, 030032
- Local Institution - 0059
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina, 100020
- Local Institution - 0061
-
Beijing, Beijing Municipality, Kina, 100043
- Local Institution - 0057
-
Beijing, Beijing Municipality, Kina, 100730
- Local Institution - 0056
-
-
Fujian
-
Fuzhou, Fujian, Kina, 350000
- Local Institution - 0123
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510000
- Local Institution - 0138
-
-
Henan
-
Zhengzhou, Henan, Kina, 450008
- Local Institution - 0051
-
-
Hubei
-
Wuhan, Hubei, Kina, 430002
- Local Institution - 0066
-
Wuhan, Hubei, Kina, 430030
- Local Institution - 0054
-
-
Hunan
-
Changsha, Hunan, Kina, 410013
- Local Institution - 0071
-
Changsha, Hunan, Kina, 410013
- Local Institution - 0103
-
-
Jiangsu
-
Nanjing, Jiangsu, Kina, 210009
- Local Institution - 0180
-
Nantong, Jiangsu, Kina, 226001
- Local Institution - 0111
-
Suzhou, Jiangsu, Kina, 215006
- Local Institution - 0104
-
Wuxi, Jiangsu, Kina, 214023
- Local Institution - 0069
-
-
Jiangxi
-
Nanchang, Jiangxi, Kina, 330006
- Local Institution - 0095
-
-
Jilin
-
Changchun, Jilin, Kina, 130021
- Local Institution - 0052
-
-
Liaoning
-
Shenyang, Liaoning, Kina, 110001
- Local Institution - 0096
-
Shenyang, Liaoning, Kina, 110004
- Local Institution - 0176
-
-
Shaanxi
-
Xi'an, Shaanxi, Kina, 710126
- Local Institution - 0060
-
-
Shandong
-
Jinan, Shandong, Kina, 250012
- Local Institution - 0072
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina, 200025
- Local Institution - 0118
-
Shanghai, Shanghai Municipality, Kina, 200080
- Local Institution - 0317
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Kina, 300060
- Local Institution - 0091
-
-
Yunnan
-
Kunming, Yunnan, Kina, 650101
- Local Institution - 0058
-
-
Zhejiang
-
Hangzhou, Zhejiang, Kina, 310003
- Local Institution - 0050
-
Wenzhou, Zhejiang, Kina, 32500
- Local Institution - 0115
-
-
-
-
-
Oslo, Norge, 0450
- Local Institution - 0081
-
-
Hordaland
-
Bergen, Hordaland, Norge, 5021
- Local Institution - 0049
-
-
Rogaland
-
Stavanger, Rogaland, Norge, 4021
- Local Institution - 0112
-
-
-
-
-
San Juan, Puerto Rico, 00909
- Local Institution - 0316
-
-
-
-
-
Brasov, Rumænien, 500052
- Local Institution - 0284
-
Bucharest, Rumænien, 022328
- Local Institution - 0302
-
Bucharest, Rumænien, 030171
- Local Institution - 0287
-
Sibiu, Rumænien, 557260
- Local Institution - 0306
-
-
Bucharest
-
Bucharest, Bucharest, Rumænien, 022328
- Local Institution - 0282
-
-
-
-
Central Singapore
-
Singapore, Central Singapore, Singapore, 119074
- Local Institution - 0158
-
Singapore, Central Singapore, Singapore, 169608
- Local Institution - 0159
-
-
-
-
-
Granada, Spanien, 18012
- Local Institution - 0107
-
Madrid, Spanien, 28015
- Local Institution - 0047
-
Málaga, Spanien, 29010
- Local Institution - 0105
-
-
Barcelona [Barcelona]
-
Badalona, Barcelona [Barcelona], Spanien, 08916
- Local Institution - 0126
-
Barcelona, Barcelona [Barcelona], Spanien, 08035
- Local Institution - 0092
-
L'Hospitalet Del Llobregat, Barcelona [Barcelona], Spanien, 08908
- Local Institution - 0038
-
-
Madrid, Comunidad de
-
Madrid, Madrid, Comunidad de, Spanien, 28009
- Local Institution - 0200
-
Majadahonda, Madrid, Comunidad de, Spanien, 28222
- Local Institution - 0108
-
-
Santa Cruz De Tenerife
-
San Cristóbal de La Laguna, Santa Cruz De Tenerife, Spanien, 38320
- Local Institution - 0201
-
-
Valenciana, Comunitat
-
Valencia, Valenciana, Comunitat, Spanien, 46010
- Local Institution - 0037
-
-
-
-
Seoul-teukbyeolsi [Seoul]
-
Seoul, Seoul-teukbyeolsi [Seoul], Sydkorea, 03080
- Local Institution - 0238
-
Seoul, Seoul-teukbyeolsi [Seoul], Sydkorea, 06351
- Local Institution - 0239
-
Seoul, Seoul-teukbyeolsi [Seoul], Sydkorea, 06591
- Local Institution - 0240
-
-
-
-
-
Kaohsiung City, Taiwan, 82445
- Local Institution - 0012
-
Taichung, Taiwan, 407
- Local Institution - 0001
-
Tainan, Taiwan, 704
- Local Institution - 0002
-
Taipei, Taiwan, 11217
- Local Institution - 0162
-
-
Chiayi
-
Chiayi City, Chiayi, Taiwan, 613
- Local Institution - 0274
-
-
Kaohsiung
-
Kaohsiung Niao Sung Dist, Kaohsiung, Taiwan, 83301
- Local Institution - 0177
-
-
-
-
-
Berlin, Tyskland, 12203
- Local Institution - 0007
-
Cologne, Tyskland, 50937
- Local Institution - 0102
-
Dresden, Tyskland, 01307
- Local Institution - 0329
-
Düsseldorf, Tyskland, 40479
- Local Institution - 0334
-
Heidelberg, Tyskland, D-69120
- Local Institution - 0015
-
Leipzig, Tyskland, 04103
- Local Institution - 0030
-
Nuremberg, Tyskland, 90419
- Local Institution - 0133
-
Würzburg, Tyskland, 97080
- Local Institution - 0014
-
-
Baden-Wurttemberg
-
Ulm, Baden-Wurttemberg, Tyskland, 89081
- Local Institution - 0124
-
-
Bavaria
-
Munich, Bavaria, Tyskland, 81241
- Local Institution - 0330
-
-
Lower Saxony
-
Hanover, Lower Saxony, Tyskland, 30161
- Local Institution - 0333
-
-
North Rhine-Westphalia
-
Dortmund, North Rhine-Westphalia, Tyskland, 44263
- Local Institution - 0335
-
-
Schleswig-Holstein
-
Kiel, Schleswig-Holstein, Tyskland, 24105
- Local Institution - 0029
-
-
Thuringia
-
Jena, Thuringia, Tyskland, 07747
- Local Institution - 0331
-
-
-
-
-
Budapest, Ungarn, 1088
- Local Institution - 0042
-
Budapest, Ungarn, 1097
- Local Institution - 0019
-
-
Baranya
-
Pécs, Baranya, Ungarn, 7624
- Local Institution - 0036
-
-
Hajdú-Bihar
-
Debrecen, Hajdú-Bihar, Ungarn, 4032
- Local Institution - 0043
-
-
Szabolcs-Szatmár-Bereg
-
Nyíregyháza, Szabolcs-Szatmár-Bereg, Ungarn, 4400
- Local Institution - 0094
-
-
-
-
-
Linz, Østrig, 4020
- Local Institution - 0020
-
Vienna, Østrig, 1090
- Local Institution - 0017
-
-
State of Vienna
-
Vienna, State of Vienna, Østrig, 1060
- Local Institution - 0266
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria
- Participant has documented diagnosis of multiple myeloma and measurable disease, defined as any of the following:.
i) Myeloma-protein (M-protein) ≥ 0.5 grams/deciliter (g/dL) by serum protein electrophoresis (sPEP), or.
ii) M-protein ≥ 200 milligrams (mg)/24-hour urine collection by urine protein electrophoresis (uPEP) or,.
iii) For participants without measurable disease in sPEP or uPEP: serum free light chain levels > 100 mg/liter (L) (10 mg/dL) involved light chain and an abnormal κ/λ free light chain ratio.
- Participant has received at least one prior line of anti-myeloma therapy. Note: One line can contain several phases (e.g., induction, [with or without] hematopoietic stem cell transplant, (with or without) consolidation, and/or [with or without] maintenance therapy).
- Participant must have received prior treatment with lenalidomide and at least 2 cycles of an anti-CD38 monoclonal antibody (mAb) (participants who were intolerant of an anti-CD38 mAb and received < 2 cycles are still eligible).
- Participant achieved minimal response or better to at least 1 prior anti-myeloma therapy.
- Participant must have documented disease progression during or after their last antimyeloma regimen.
Exclusion Criteria
- Participant who has had prior treatment with mezigdomide or carfilzomib.
- Participant has previously received allogeneic stem cell transplant at any time or received autologous stem cell transplant within 12 weeks of initiating study treatment.
- Other protocol-defined Inclusion/Exclusion criteria apply.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Kd (Carfilzomib + Dexamethason)
|
Specified dose on specified days
Andre navne:
Specified dose on specified days
Andre navne:
|
|
Eksperimentel: MeziKd (Mezigdomide + Carfilzomib + Dexamethason)
|
Specified dose on specified days
Andre navne:
Specified dose on specified days
Andre navne:
Specified dose on specified days
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Progressionsfri overlevelse (PFS)
Tidsramme: Op til cirka 5 år
|
Op til cirka 5 år
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Progressionsfri overlevelse 2 (PFS-2)
Tidsramme: Op til cirka 5 år
|
Op til cirka 5 år
|
|
|
Samlet overlevelse (OS)
Tidsramme: Op til cirka 5 år
|
Op til cirka 5 år
|
|
|
Tid til svar (TTR)
Tidsramme: Op til cirka 5 år
|
Op til cirka 5 år
|
|
|
Varighed af svar (DOR)
Tidsramme: Op til cirka 5 år
|
Op til cirka 5 år
|
|
|
Tid til Progression (TTP)
Tidsramme: Op til cirka 5 år
|
Op til cirka 5 år
|
|
|
Tid til næste behandling (TTNT)
Tidsramme: Op til cirka 5 år
|
Op til cirka 5 år
|
|
|
Minimal Residual Disease (MRD) negativitetsrate
Tidsramme: Op til cirka 5 år
|
Op til cirka 5 år
|
|
|
Antal deltagere med uønskede hændelser (AE'er)
Tidsramme: Op til cirka 5 år
|
Op til cirka 5 år
|
|
|
Samlet svar (OR)
Tidsramme: Op til cirka 5 år
|
Op til cirka 5 år
|
|
|
Recommended Mezigdomide Dose
Tidsramme: Up to 12 months
|
Stage 1 only |
Up to 12 months
|
|
Plasma concentrations of Mezigdomide in Combination with Carfilzomib and Dexamethasone
Tidsramme: Up to 176 days
|
Stage 1 only |
Up to 176 days
|
|
Rate Of Very Good Partial Response (VGPR) Or Better (VGPRR)
Tidsramme: Up to approximately 5 years
|
VGPRR will be calculated as the percentage of participants who achieve best response of VGPR or better according to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma. |
Up to approximately 5 years
|
|
Complete Response (CR) Or Better (CRR)
Tidsramme: Up to approximately 5 years
|
CRR will be calculated as the percentage of participants who achieve best response of CR or better according to the IMWG Uniform Response Criteria for Multiple Myeloma. |
Up to approximately 5 years
|
|
Change From Baseline in the European Organization for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30)
Tidsramme: Up to approximately 5 years
|
The EORTC QLQ-C30 is the most commonly used quality of life instrument in oncology trials. The QLQ-C30 consists of 30 questions incorporated into 5 functional domains physical, role, cognitive, emotional, and social), 9 symptom/other scales (fatigue, pain, nausea and vomiting, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties), and a single global Quality of Life (QoL)/global health status score. Items in the functional and symptom scale use raw participant response of 1 to 4, where 1 = "not at all" and 4 = "very much." The 2 global items contain responses ranging from 1 "very poor" to 7 "excellent." The recall period is 1 week. All domain scores are transformed in a range from 0 to 100, where a higher functional score indicates more favorable outcomes and a higher score on the symptom domains indicates a less favorable participant outcome. Stage 2 only. |
Up to approximately 5 years
|
|
Change From Baseline in the European Quality of Life Multiple Myeloma Module (EORTC QLQ-MY20)
Tidsramme: Up to approximately 5 years
|
The EORTC QLQ-MY20 is a 20-item myeloma module intended for use among participants varying in disease stage and treatment modality. Participants rate symptoms or problems on a scale from 1 to 4 where 1 = "not at all" and 4 = "very much." Stage 2 only. |
Up to approximately 5 years
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Bristol-Myers Squibb, Bristol-Myers Squibb
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Karsygdomme
- Hjerte-kar-sygdomme
- Patologiske processer
- Neoplasmer
- Sygdomsegenskaber
- Sygdomme i immunsystemet
- Neoplasmer efter histologisk type
- Hæmatologiske sygdomme
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Neoplasmer, Plasmacelle
- Hæmostatiske lidelser
- Paraproteinæmier
- Blodproteinforstyrrelser
- Hæmoragiske lidelser
- Patologiske tilstande, tegn og symptomer
- Hemiske og lymfatiske sygdomme
- Tilbagevenden
- Myelomatose
- Svovlforbindelser
- Organiske kemikalier
- Kulbrinter
- Kulbrinter, cyklisk
- Kulbrinter, aromatisk
- Polycykliske forbindelser
- Gravidier
- Graviditet
- Steroider
- SMUSED-RING-forbindelser
- Steroider, fluoreret
- Benzenderivater
- Sulfonsyrer
- Svovlsyrer
- Gravideretrioler
- Benzenesulfonater
- Arylsulfonater
- Arylsulfonsyrer
- Dexamethason
- Calciumdobesilat
- carfilzomib
Andre undersøgelses-id-numre
- CA057-008
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
IPD-delingstidsramme
See Plan Description
IPD-delingsadgangskriterier
See Plan Description
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- CSR
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .